文献速递肝病消化道肿瘤与早癌

替诺福韦与恩替卡韦治疗慢性HBV感染的5年HCC发生风险相似:法国AFEF/ANRS CO22 Hepather队列研究

Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.
PubMed 文献 · Aliment Pharmacol Ther · 2021-01-19

该前瞻性队列研究纳入1800例接受替诺福韦或恩替卡韦治疗超过6个月的慢性HBV感染者,中位随访4.2年,采用逆概率治疗加权比较两组结局。结果显示两组HCC、肝硬化失代偿、肝移植、全因死亡、肝相关死亡及复合终点的发生率均无显著差异。

要点

  • 替诺福韦与恩替卡韦治疗者5年内HCC及肝相关事件风险相似。
  • 研究人群以非肝硬化法国患者为主,中位随访4.2年。
  • 两组复合终点发生率分别为4.1和5.0/1000人年,无显著差异。

核心结论

  • 在主要以非肝硬化法国患者组成的大型前瞻性队列中,替诺福韦与恩替卡韦治疗者的肝相关事件或死亡风险无差异。

研究设计与样本

  • 前瞻性队列研究(ANRS CO22 Hepather),纳入1800例接受替诺福韦(986例)或恩替卡韦(814例)治疗超过6个月的慢性HBV感染者,排除HDV/HCV合并感染或既往肝脏事件者,采用逆概率治疗加权比较事件发生率。

主要发现

  • 替诺福韦组HCC发生率为1.8(0.9; 3.2)/1000人年,恩替卡韦组为1.6(0.7; 3.0)/1000人年。
  • 替诺福韦组肝硬化失代偿发生率为0.6(0.2; 1.6)/1000人年,恩替卡韦组为0.7(0.2; 1.8)/1000人年。
  • 替诺福韦组肝移植发生率为0.2(0.0; 0.8)/1000人年,恩替卡韦组为0.2(0.0; 1.0)/1000人年。
  • 替诺福韦组全因死亡发生率为1.7(0.8; 3.0)/1000人年,恩替卡韦组为3.0(1.7; 4.8)/1000人年。
  • 替诺福韦组肝相关死亡发生率为0.8(0.2; 1.8)/1000人年,恩替卡韦组为0.5(0.1; 1.5)/1000人年;复合终点发生率分别为4.1(3.0; 5.4)和5.0(3.3; 7.2)/1000人年。

临床怎么用

  • 对于慢性HBV感染者,替诺福韦和恩替卡韦均可作为一线核苷(酸)类似物选择,两者在肝相关结局上未见显著差异。

局限性

  • 研究人群以非肝硬化法国患者为主,中位随访4.2年,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications. AIM: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort. METHODS: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW). RESULTS: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively. CONCLUSION: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients. TRIAL REGISTRATION NUMBER: NCT019553458.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pol S. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort. Aliment Pharmacol Ther. 2021. PMID: 33464621. doi:10.1111/apt.16197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。